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Abstract
Researchers have linked dementia to common psychiatric symptoms such as agitation
and aggression, known as behavioral and psychological symptoms of dementia (BPSD).
To treat residents manifesting BPSD, nursing homes (NHs) use psychoactive
medications. However, research is limited and inconsistent regarding the impact of
Depakote treatment on agitation and short-term memory (STM) in NH residents who
have dementia. The purpose of this nonexperimental quantitative study was to evaluate
for 1 year the impact of Depakote treatment on agitation and STM in NH residents as
measured by each resident’s Minimum Data Set (MDS). Moncrieff and Cohen’s drugcentered theory served as the theoretical foundation for the study. Archival data from the
consulting pharmacist and NH MDS included 16 NH dementia residents. Data were
analyzed using a repeated-measures within-subject ANOVA. Results indicated no
significant impact of Depakote treatment on agitation and STM scores over a 1-year
period. Results may be used to assess the impact and efficacy of a common yet largely
unexamined invasive treatment on an underserved, vulnerable population.
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Chapter 1: Introduction to the Study
Dementia, a progressive and irreversible loss of cognitive functioning caused by
brain cell damage (Desai, Heaton, & Kelton, 2012), affects approximately 5 to 8 million
Americans. More than half of those afflicted have common psychotic symptoms along
with aggression, agitation, and cognitive decline (Mittal, Kurup, Williamson, Muralee, &
Tampi, 2011). These symptoms collectively are termed behavioral and psychological
symptoms of dementia (BPSD). BPSD is the most common reason for nursing home
(NH) admission (Meinhold et al., 2005), and psychoactive medications (e.g., Depakote)
are the most common treatment for BPSD in the NH setting (Richter, Mann, Meyer,
Haastert, & Köpke, 2011). However, there is only limited research on the impact of this
treatment. Studies (Desai et al., 2012; Mittal et al., 2011) showed inconsistent results
among disparate populations. The current quantitative study addressed the impact of
Depakote on agitation and short-term memory (STM) in NH residents with dementia over
a 1-year period. Positive social change implications included (a) contribution to the
limited extant research on this important subject and (b) assessment of the impact and
efficacy of a common yet largely unexamined invasive treatment on an underserved,
vulnerable population.
Chapter 1 provides a brief overview of research literature related to the impact of
Depakote on agitation and STM in NH residents with dementia and the research gap on
this topic. Also, the significance of the research problem to the field of psychology is
discussed. The quantitative design and independent/dependent variables of the study are
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described. Chapter 1 also includes the research questions and null and alternative
hypotheses, including an explanation of how they related to the study approach and
research questions. Next, the nature of the study (including design, variables, and
methodology) is discussed. Definitions are provided for operative variables and terms.
Finally, assumptions, scope, limitations, and significance of the study are discussed.
Background
Dementia is common in the older adult population and is characterized by
agitation, aggression, disorientation, cognitive decline, verbal and physical outbursts, and
decline in eating, sleeping, walking, and talking (Dharmarajan & Gunturu, 2009). These
characteristics of dementia—collectively referred to as BPSD—affect not only the
individual with dementia but also his or her loved ones and caregivers. The impact of
dementia on the afflicted individual’s support system often leads the family to turn to
nursing homes (NHs). According to Dutcher et al. (2014), 30-40% of individuals with
Alzheimer’s Disease (AD) and other forms of dementia in the United States reside in
NHs, where psychoactive medications (e.g., Depakote) are the most common treatment
(Richter et al., 2011). Depakote is an anticonvulsant medication often used to manage
agitation, which occurs in most NH residents with dementia (Meeks & Jeste, 2008).
Although there is a vast amount of literature regarding Depakote used for agitation and its
effects on cognition, the studies indicated inconsistent results. Dutcher et al. (2014)
reported Depakote had no significant effect on slowing cognitive decline; in contrast,
Meinhold et al. (2005) reported marginal improvement in STM. There remains a gap in
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the literature regarding the impact of Depakote on agitation and STM in NH dementia
residents. The current study addressed that gap and helped provide avenues for social
change by providing new information on the most common treatment (i.e., Depakote) for
a prevalent and exigent societal problem (i.e., BPSD).
Problem Statement
Although the most ostensible feature of dementia is a cognitive decline,
behavioral disturbances, also referred to as neuropsychiatric symptoms or BPSD, are
often present and cause difficulty in managing NH residents with dementia (Pinheiro,
2008). BPSD, which commonly manifests as agitation, has no FDA approved treatment
(Desai et al., 2012). Although various treatment options exist for BPSD in NH residents
with dementia, psychoactive medications continue to be the most widely used to manage
BPSD despite reports of inconsistent benefits and adverse effects (Rayner, O’Brien, &
Schoenbachler, 2006). Psychoactive medications, such as the anticonvulsant Depakote,
have been proven to have adverse effects in NH residents with dementia (Dutcher et al.,
2014). Dolder, Nealy, and McKinsey (2012) postulated that anticonvulsants such as
Depakote are commonly used to manage agitation and aggression because of a lack of
alternative treatment options that balance efficacy and safety. Lack of scientific
consensus in the relevant literature indicated a need for additional studies. The results of
the current study may be used to assess the impact and efficacy of a common yet largely
unexamined invasive treatment on an underserved, vulnerable population.
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Purpose of the Study
The purpose of this quantitative study, which included a nonexperimental design,
was to examine the impact of Depakote on agitation and STM in NH residents with
dementia within a 1-year period. The independent variable was Depakote treatment, and
the dependent variables were agitation and STM. The focus of this study was to
determine to what extent Depakote affects levels of agitation and STM. There was also a
variable of interest, effect over time (trials). Boxplots were used to determine whether the
length of time the resident was receiving Depakote had any significant effect on agitation
and STM scores.
Research Questions and Hypotheses
Research Question 1 (RQ1): To what extent does Depakote treatment affect levels
of agitation in NH dementia residents over a 1-year period?
H01: There is no statistically significant difference in levels of agitation with
Depakote treatment over a 1-year period as evidenced by no change in agitation from
preexisting data in Section E of the MDS.
Ha1: There is a statistically significant difference in levels of agitation with
Depakote treatment over a 1-year period as evidenced by decreased agitation from
preexisting data in Section E of the MDS.
Research Question 2 (RQ2): To what extent does Depakote treatment affect STM
in NH dementia residents over a 1-year period?
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H02: There is no statistically significant difference in STM with Depakote
treatment over a 1-year period as evidenced by no change in STM functioning from
preexisting data in Section C of the MDS.
Ha2: There is a statistically significant difference in STM with Depakote
treatment over a 1-year period as evidenced by decreased STM functioning from
preexisting data in Section C of the MDS.
Theoretical Framework for the Study
Moncrieff and Cohen’s (2009) drug-centered theory was the theoretical
framework for this study. According to drug-centered theory, psychoactive medications
are extrinsic substances that alter how the body works, and the advantages and
disadvantages of psychoactive medication use should be carefully evaluated and
distinguished from the effects of treatment in general. Drug-centered theory can help
identify (a) how psychoactive medications interact with/induce experiences of distress
and (b) when the medicated individual should seek psychological help.
Previous theories of psychoactive medication prescription acted to counter
neurochemical substrates of disorders or symptoms (Moncrieff, 2008; Moncrieff, Cohen,
& Mason, 2009). Neglecting to consider potential psychoactive effects of the psychiatric
medications have made it difficult for researchers to establish disease-specific actions and
to distinguish whether outcomes occur because of the medication’s actions on an
underlying pathological process or as a consequence of being in an altered state
(Moncrieff & Cohen, 2009). There are many disorders that can mimic psychoactive
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effects, such as sedation, cognitive slowing, behaviors, altered sense of perception, sleep,
and psychosis. Drug-centered theory indicates that although evidence of the superiority of
psychoactive medications might imply disease-specific effects, superior effects can also
be explained within a drug-centered framework, which suggests that the characteristic
psychomotor and emotional restriction induced by psychoactive medications is more
effective at suppressing psychotic agitation than other sedatives.
Moncrieff and Cohen’s (2009) drug-centered theory directly related to this study
by providing residents or staff members the ability to evaluate and report effects of
Depakote treatment in their particular situations. The drug-centered theory has also
prompted the psychiatric research community to produce relevant, unbiased information
about the range of short- and long-term psychoactive medication effects on cognition,
behaviors, and bodily systems. The drug-centered theory is discussed in more detail in
the Chapter 2 literature review.
Nature of the Study
This quantitative study addressed to what extent Depakote treatment affects levels
of agitation and STM in NH residents with dementia. Also, levels of agitation and STM
for Depakote treatment were measured in four intervals over a 1-year period with and
without random effects. Residents’ levels of agitation and STM were measured using the
NH’s preexisting quarterly MDS assessments. I used a repeated measures ANOVA
design with within-subject effects. A Depakote trial group was measured over four
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intervals in a 1-year period, and effect over time (with and without random effects)
provided adequate statistical power.
The dependent variables for this study were agitation and STM, and the
independent variable was Depakote treatment measured by MDS results and scores.
Many NH residents with dementia receive psychoactive medications with questionable
benefits. Looking at these variables provided an understanding of how Depakote
treatment in dementia patients impacted agitation and STM within the sample.
Variables were analyzed using a repeated-measures within-subject (with and
without random effects) ANOVA. The repeated-measures ANOVA was the appropriate
design for this study because it allowed for testing one group while subjecting them to
repeated measures. This study had one independent variable (Depakote treatment group),
two dependent variables (agitation and STM), and significant trials effect (trials/multiple
measures over time), followed up with boxplots to determine whether the length of time
the resident was receiving Depakote played any significant role in agitation scores and
STM scores. A repeated measures design was used because all preexisting data were
measured on each variable.
I used archival data from an existing dataset. I did not have direct contact with
residents, which obviated potential ethical issues from dealing with a vulnerable,
cognitively impaired population. Data were gathered from a consulting pharmacy’s
database and NH MDS to measure the impact of Depakote on agitation and STM in NH
dementia residents. This system of data gathering ensured that data reflected residents
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who (a) had been diagnosed with dementia, (b) had exhibited BPSD, and (c) had been
receiving Depakote over a 1-year period. MDS is a tool mandated for use in NHs for
clinical assessments of all residents covered under Medicare and Medicaid. The MDS
provides a comprehensive assessment of each resident’s functional capabilities, healthrelated issues, behaviors, psychological symptoms, and cognitive functioning. The MDS
is described in more detail in Chapter 3.
Definitions of Key Terms
Agitation: An increased verbal and/or motor activity as well as restlessness,
anxiety, tension, and fear with or without provocation (Zagaria, 2006).
Alzheimer’s disease (AD): The most common type of dementia, characterized by
cognitive impairment, difficulty communicating, poor judgment, disorientation,
confusion, behavior changes, and difficulty speaking, swallowing and walking
(Alzheimer’s Association, 2017).
Behavioral and psychological symptoms of dementia (BPSD): A heterogeneous
range of psychological reactions, psychiatric symptoms, and behaviors, which may be
disruptive and unsafe and may impair patient care (Mittal et al., 2011).
Dementia: A general term for memory loss and other mental abilities caused by
physical changes in the brain that interfere with daily life (Alzheimer’s Association,
2017).
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Depakote: An anticonvulsant medication originally developed to treat epilepsy
and bipolar disorder and to prevent migraine headaches; it can be given intravenously or
orally and has long- and short-acting forms (FDA, 2011).
Psychoactive medications: Drugs or chemical substances that act primarily on the
central nervous system and alter brain function, resulting in temporary changes in
behavior, mood, perception, and consciousness (Brandt & Pyhtila, 2013).
Short-term memory (STM): The type of memory used to retain information for a
short time; it has a working memory component that is used to manipulate information in
consciousness (Engle, Laughlin, Tuholski, & Conway, 1999).
Assumptions
I assumed that all residents were NH residents of one of the two local NHs from
which data were obtained. This assumption was accounted for by obtaining preexisting
data directly from the two NHs. I also assumed that all residents had a diagnosis of
dementia. The preexisting data from the pharmacy consultant and the two NHs verified
residents’ diagnosis of dementia. Next, I assumed that the residents were receiving
Depakote for BPSD, which was also accounted for by viewing the preexisting data from
the pharmacy consultant. This dataset included the reason why the residents were
receiving Depakote. I assumed that assessment tools used in this study were appropriate
for the identified sample of NH residents with dementia on Depakote treatment for
agitation. I assumed all data gathered were preexisting data from NH MDS and pharmacy
records and were as accurate as possible, entailing a further assumption that NH staff
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members completing the MDS had the clinical knowledge/competency to do so. I
assumed that anonymity and confidentiality were preserved by using preexisting data and
that use of these data obviated potential ethical concerns.
Scope and Delimitations
I examined the impact of Depakote on agitation and STM in NH dementia
residents over a 1-year period. This area was chosen for this study because prior research
indicated adverse effects of psychoactive medications but revealed a gap on the impact of
Depakote on agitation and STM in NH dementia residents over a 1-year period. The
sample was chosen to represent NH residents receiving Depakote for BPSD. This study
did not include unmeasured variables, such as gender, race, and age, because of the
smaller sample size. Residents receiving Depakote for seizure disorder were excluded.
Prior research indicated adverse effects of Depakote, but this study looked specifically at
the impact of Depakote on agitation and STM in NH dementia residents within a 1-year
period. The primary issues of validity were anticipating that NH social workers who
completed preexisting MDSs provided correct information regarding each resident’s
behavior and cognition.
Limitations
Limitations of this study pertained to potential problems with the study design.
For example, the NHs where the data were gathered represented only the United States
and may not represent the entire NH population. Data were drawn from a specific
population, and the sample size was limited due to the study requirements of (a) residents
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had been on Depakote treatment for one year and (b) Depakote having been prescribed
specifically for BPSD. This study did not include every race, age bracket, geographic
background, or socioeconomic status represented in the NHs. Threats to external validity
related to repeated measures because it was difficult to control for the effects of prior
outcomes using the same subject.
Another factor that contributed to limitations in this study was the lack of primary
data (i.e., depending exclusively on accurate MDS assessments). Data in MDS and
pharmacy records may not have been meticulously and accurately collected. However,
because of the vulnerable nature of the target population, it was best to use preexisting
data to avoid ethical complications when gathering the data. Clear directions were given
to the NH and pharmacy contacts regarding the specific sections needed from MDS
records and pharmacy records (i.e., only residents who had been on Depakote for BPSD
for at least one year, with seizures excluded). Nevertheless, there were factors that could
have jeopardized internal validity (e.g., if the scorer of the MDS changed, there may have
been outcome changes). Precautions were taken to maintain the confidentiality of the data
provided, and NH administrators and pharmacy representatives were informed that the
study would be confidential.
Significance of the Study
Over the last century, there has been a dramatic increase in psychoactive
medication use due to the increase in the geriatric population, and patient
pharmacokinetic and pharmacodynamic responses to these medications differ
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considerably (Hilmer, McLachlan, & Le Couteur, 2007). There is limited evidence
regarding the complexities of geriatric pharmacology, and it is underappreciated in
clinical trials.
According to Spira and Edelstein (2007), agitation is exhibited by 55% to 90% of
individuals with dementia with various approaches and treatments attempted.
Psychoactive medications are prescribed to up to a third of older adults and are the most
widely used medications in NHs to treat agitation, Depakote being one of them
(Huybrechts et al., 2012). Understanding potential connections between agitation and
STM with Depakote treatment may contribute to positive social change by raising
awareness regarding concerns of the NH dementia population that may have been
overlooked. It is important to understand the theoretical concepts behind psychoactive
medication use, agitation, and memory in those with dementia. It is essential to treat these
symptoms in this population, but research indicated that there had not been any
therapeutic solutions and Depakote continues to be used for these purposes. This study
addressed that gap by examining the impact of Depakote on agitation and STM in NH
dementia residents over a 1-year period. Findings from this study may provide insight on
the impact of Depakote used to treat agitation and its adverse effects about agitation and
STM. Findings may provide updated information related to NH use of Depakote for
managing BPSD in an underserved, vulnerable population.
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Summary
Chapter 1 provided a brief overview of existing literature on the study topic,
including a gap in the literature regarding the impact of Depakote treatment on agitation
and STM. I gave a brief description of drug-centered theory as the theoretical framework
for this study. The NH is a unique environment that requires workers to be trained to deal
with dementia and BPSD. BPSD is difficult to manage in NH dementia residents, and
therefore psychoactive medications are often used (Meeks & Jeste, 2008). Studies
showed Depakote treatment as inconsistent, with positive and negative effects. Despite
conflicting findings and safety warnings concerning the use of psychoactive medications
in NH residents, Depakote treatment has remained common because of longer resident
lifespans and an increased number of people with dementia (Huybrechts et al., 2011).
This study contributed to the body of literature by addressing the impact of Depakote
treatment on agitation and STM in NH dementia residents over a 1-year period.
Implications for social change include assessing the impact and efficacy of a common yet
largely unexamined invasive treatment on an underserved, vulnerable population.
Chapter 2 provides a more comprehensive overview of drug-centered theory, which
provided the theoretical framework for studying the impact of Depakote on agitation and
STM in NH dementia residents within a 1-year period. Chapter 2 also addresses
inconsistencies in the extant literature concerning the impact of Depakote on agitation
and STM.
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Chapter 2: Literature Review
A review of the literature produced a limited number of studies on the impact of
Depakote on agitation and STM in NH dementia residents. The purpose of this
nonexperimental quantitative study was to go beyond the boundaries of the current
literature to examine the impact of Depakote treatment on agitation and STM in NH
dementia residents over a 1-year period. The focus was on the extent to which Depakote
affects levels of agitation and STM. The Depakote treatment group was the independent
variable; agitation and STM were the dependent variables. I employed a within-subject
design (trials/effects over time), including repeated measures for all variables.
Additionally, I employed boxplots to determine whether the length of time resident was
receiving Depakote had any significant effect on agitation scores and STM scores.
Depakote is an anticonvulsant medication used to manage agitation in
approximately 80% of NH residents with dementia (Meeks & Jeste, 2008). Medicare
reports show dementia affects approximately 5 to 8 million Americans, of which more
than half have BPSD (Mittal et al., 2011). According to Dutcher et al. (2014), 30-40% of
individuals with AD and other forms of dementia in the United States reside in NHs.
BPSD is a major reason for increased agitation and cognitive decline, for which there is
no FDA approved treatment (Desai et al., 2012).
The following literature review includes the most current research relating to NH
residents with a diagnosis of dementia who are prescribed Depakote for BPSD. The
collective body of literature informed this study of the impact of Depakote on NH
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dementia resident behaviors, psychological symptoms, and cognition. This chapter begins
with a description of the literature search strategy. The next section contains a review of
literature on Moncrieff and Cohen’s (2009) drug-centered theory and is followed by a
review of studies on psychoactive medication use in NH dementia residents, Depakote
use in NH dementia residents, adverse effects of Depakote use in NH dementia residents,
benefits of Depakote use in NH dementia residents, BPSD and Depakote use in NH
dementia residents, Depakote and agitation in NH dementia residents, Depakote and
cognitive functioning in NH dementia residents, and Depakote and STM in NH dementia
residents. Next is a review of studies that addressed Depakote use to manage agitation in
NH dementia residents, a review that exposes inconsistencies in findings and effects of
Depakote use to manage agitation in NH dementia residents. Some of the studies cited in
this literature review involved the use of MDS to obtain measures of behavior and/or
cognitive functioning (i.e., the same database that was used in the current study). Finally,
the study variables are discussed (i.e., Depakote use, agitation, and STM), and an
explanation for the impact of Depakote on agitation and STM in NH dementia residents
is provided. The chapter concludes with a rationale for the choice of research method, a
summary of the literature review, and suggestions for additional research.
Literature Search Strategy
The databases used to discover the literature were accessed through the Walden
University Library; the databases included PsychINFO, SAGE Premier, Academic
Search Complete, PsychARTICLES, ProQuest Central, MEDLINE, and BIOMED
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Central. I also used the Google Scholar search engine. The following keywords, terms,
and phrases were used: dementia, AD, agitation, BPSD, STM, cognition, Depakote, NH
residents, psychoactive medications, Depakote and agitation and dementia, Depakote
and BPSD, Depakote and agitation and NH residents, Depakote and NH, effects and
Depakote and agitation, Depakote and cognition, Depakote and STM and dementia,
Depakote and AD, and psychoactive medications and NH. Most of the literature was
found using SAGE Premier and Google Scholar, and the search using the phrase
Depakote and BPSD yielded the most literature. Initial searches were performed in
October 2015, and additional searches were conducted for new references in May 2016,
July 2016, and January 2017.
Theoretical Foundation: Drug-Centered Theory
The theoretical framework for this study was Moncrieff and Cohen’s (2009) drugcentered theory, which states that because psychoactive medications are extrinsic
substances altering how the body works, advantages and disadvantages of psychoactive
medication use should be weighed and distinguished from the effects of treatment in
general. Drug-centered theory can inform perspectives about how psychological
alterations produced by psychoactive medications interact with experiences of distress
and the need to seek psychological help. Many disorders can mimic psychoactive effects,
such as sedation, cognitive slowing, behaviors, altered sense of perception, sleep, and
psychosis.
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Moncrieff and Cohen (2009) theorized that although evidence of the superiority
of psychoactive medications might imply disease-specific effects, superior effects can
also be explained within a drug-centered framework (e.g., the psychomotor and
emotional restriction characteristic of psychoactive medications suppresses psychotic
agitation more effectively than other sedatives). The drug-centered theory provides a
useful lens through which NH resident clinicians or staff members can evaluate and
report the effects of Depakote treatment in NH dementia residents. The drug-centered
framework further prompts members of the psychiatric research community to produce
relevant, unbiased information about the short- and long-term effects of psychoactive
medications on cognition, behaviors, and bodily systems.
Literature Review Related to Key Variables
Overview of Psychoactive Medication Administration in Treating BPSD in NH
Dementia Residents
Throughout much of the literature reviewed, dementia-associated psychotic
symptoms have been labeled BPSD, which represents the most difficult dementia
sequelae for NHs to manage. BPSD is often discussed in the literature as a heterogeneous
range of psychological reactions, psychiatric symptoms, and behaviors, which can be
disruptive and unsafe and can impair the care of the resident in a given environment;
moreover, the likelihood and intensity of BPSD increase as dementia progresses (Mittal
et al., 2011).
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Meeks and Jeste (2008) conducted a meta-analysis of 15 randomized controlled
trials involving psychoactive medications including risperidone, olanzapine, aripiprazole,
and quetiapine used to treat agitation or psychosis in NH dementia residents. Most
residents were female NH residents with AD. Meeks and Jeste found that psychosis
improved with risperidone, and neuropsychiatric disturbances improved with risperidone
and aripiprazole. Meeks and Jeste also noted that effects were more noticeable in
residents without psychosis, NH residents, and residents with severe cognitive
impairment. In contrast, subsequent placebo-controlled trials of risperidone, quetiapine,
and aripiprazole in AD residents revealed that atypical and typical antipsychotics are
effective in reducing aggression and psychosis (Meeks & Jeste, 2008). Although these
findings suggested that psychoactive medications are effective in treating BPSD, the
results were questioned by the National Institute of Mental Health (NIMH) Clinical
Antipsychotic Trial of Intervention Effectiveness Study for Alzheimer’s Disease
(Lieberman, 2006). This NIH-sponsored study indicated that risperidone and olanzapine
but not quetiapine were effective in that fewer residents taking them versus placebo
dropped out due to lack of efficacy. The year-long study indicated that antipsychotics
were not effective overall because of the primary outcome, all-cause discontinuation rate,
was similar for all three drugs and placebo. The result suggested a muddled, inconclusive
picture regarding the efficacy of psychoactive medication administration for treating
BPSD in NH residents with dementia; this inconclusiveness created the need for further
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examination of a prevalent treatment program for a pressing societal problem, a need
addressed by this study.
Risks of Psychoactive Medication Use in NH Dementia Residents
There are no drugs that have been FDA approved to treat BPSD in dementia
residents, but psychoactive medications are often used to alleviate these symptoms
(Meeks & Jeste, 2008). One of the most concerning issues regarding NH administration
of psychoactive medications is they present a safety hazard and are linked to a variety of
negative outcomes (Molinari et al., 2013). In the NH setting, negative outcomes include
cerebrovascular effects, heart failure, and sudden death (Schneider, Dagerman, & Insel,
2006). According to Meeks and Jeste (2008), the likelihood that NH residents are on a
variety of medications for various health issues further complicates the administration of
psychoactive medications, thereby increasing the chances for adverse drug reactions and
potentially increasing psychosis and agitation.
BPSD Versus Other MH Symptoms
There are many side effects from psychoactive medication use in NH dementia
residents. For example, NH residents with dementia face greater risk of hospitalization,
falls, cognitive impairment, and mortality (Ballard et al., 2009, 2011; Belleville, 2010;
Cooper, Freeman, Cook, & Burfield, 2007; Dragonich, Zancy, Klafta, & Karrison, 2001;
Frey, Ortega, Wiseman, Farley, & Wright, 2011). BPSD represents just one of the
prevailing mental health (MH) concerns among the NH population. According to
Molinari et al. (2013), NH dementia residents with behavioral issues are often
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categorized as having BPSD rather than being carefully evaluated for other MH issues.
Using the benchmarks of decreased numbers of falls and hospitalizations, Molinari et al.
addressed the question of whether providing an MH assessment to all NH residents upon
admission would decrease the use of psychoactive medications. The study was conducted
at four for-profit NHs and included 23 residents who were cognitively able to provide
valid responses. These results were compared to a group of 23 NH residents who did not
receive MH assessments. Using a chi-square analysis, Molinari et al. found at a 1-month
follow-up comparing the assessment and nonassessment groups on various measures of
psychopharmacological and nonpsychopharmacological interventions that the residents
who received brief MH assessments were less likely to start on psychoactive medications
despite the fact that a high number of residents were admitted to the facility with orders
for psychoactive medications. Molinari et al. also revealed that despite favorable
comparisons with the nonassessment comparison group, psychoactive medication use
was still high in the assessment group, and the intervention was not helpful in getting
residents off psychoactive medications.
In other words, Molinari et al. (2013) found that consideration of alternative ways
of addressing residents’ MH needs decreased the likelihood of starting residents on
psychoactive medications. Also, Molinari et al. found that residents who received the MH
assessment were also more likely to receive subsequent MH consultation. This finding is
significant in that it shows a positive correlation between consideration of alternative MH
treatments and the need for a psychoactive medication regimen. This approach may be
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used to minimize previously demonstrated negative impacts of psychoactive medication
administration on NH residents with dementia. However, the study would have benefitted
from larger sample size and more diverse demographics, which would have increased
study power and validity. The sample was disproportionately non-Hispanic White and
comprised short-stay residents.
Psychoactive Medications on Mental, Behavioral, and Physical Health
Richter et al. (2011) found that psychoactive medications induce a distinctive
alteration in mental and physical states when used to treat BPSD in NH residents with
dementia. Moncrieff, Cohen, and Porter (2013) addressed how the effects of psychoactive
medications might modify various psychiatric symptoms. For example, psychoactive
effects can directly modify mental and behavioral symptoms and affect the results of
placebo-controlled trials. Although the term psychoactive is related to mental alterations,
mental conditions are connected to physical conditions, causing a global effect.
Moncrieff et al. concluded that despite much of the research in neuropharmacology, more
extensive research is needed to clarify the long-term mental, behavioral, and physical
effects of psychoactive medications. Such research would assist in diagnosis and
treatment and enable further discussion of the purpose and ethics of the frequent use of
psychoactive medications to manage behaviors in older adults.
Prevalence of Psychoactive Medication Use in NH Dementia Residents
Much of the literature addressed the challenges for NHs in managing BPSD as
well as the distress that BPSD causes residents, leading to excessive use of psychoactive
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medications. Previous research indicated psychoactive medications are the most widely
used medications among NH residents and that 50% to 80% of residents are on at least
one psychoactive medication (Meinhold et al., 2005; Richter et al., 2011). Richter et al.
(2011) looked at the comparison of four different variables (i.e., psychoactive
medication, different classes of psychoactive medication, psychoactive medication
administered for bedtime only, and associations between prescription of psychoactive
medications and institutional and resident characteristics). Richter et al. conducted a
cross-sectional comparison of data from three large studies of 5,336 NH residents from
136 long-term care facilities. Richter et al. found that in all three comparison studies,
74.6%, 51.8%, and 52.4% of all residents were on at least one psychoactive medication.
Another comparison indicated that 66% and 47% of residents were prescribed for
bedtime use only. None of the three studies indicated a statistically significant association
between psychoactive medication prescription and NH characteristics; however,
consistent positive associations were found for a higher level of care dependency and
permanent restlessness, and consistent negative associations were found for older age and
male gender. In other words, residents requiring more care and presence of permanent
restlessness had a higher rate of psychoactive medications prescribed. These findings
provide evidence that psychoactive medications are highly prevalent in managing BPSD
in NH residents. The researchers were not able, however, to show a correlation between
NH characteristics and psychoactive medication prescription rates. In contrast, despite the
important role of nursing staff, there was no impact on psychoactive medication
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prescriptions on a nurse staffing level. Specifically, it was found that psychoactive
medications are the first course of treatment for BPSD and that there is a need for
effective programs to reduce prescription of psychoactive medications in NH residents.
Impact of Depakote on Agitation in NH Dementia Residents
Agitation affects up to 70% of older adults with dementia, and Depakote
derivatives have been used for more than ten years to control agitation in dementia
residents in NHs (Narayana, Clifton, Luxenberg, & Curran, 2014). The Narayana et al.
2014 review examined whether the evidence supports the use of Depakote in the
treatment of agitation in dementia residents. The review concluded that Depakote does
not improve agitation in dementia but increases the frequency of side effects. Within the
body of literature that has focused on using Depakote for agitation in NH dementia
residents, there is limited research discussing the impact of Depakote on agitation and
STM in NH dementia residents.
Advantages of Depakote Use in NH Dementia Residents
BPSD is known to occur in up to 90% of individuals with dementia at some point
in their disease progression (Meinhold et al., 2005). There are many different
manifestations of dementia, including cognitive decline, alterations in
mood/thought/behavior, and inability to conduct activities of daily living (ADLs). As in
the Richter et al. study, Meinhold et al. (a) described BPSD as depression, hallucinations,
delusions, agitation, aggression, combativeness, disinhibition, and hyperactivity and (b)
found that pharmacological measures are often used to control agitation and aggression in
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patients with dementia. The impact or benefits of psychoactive medications are not
exclusive to one specific medication; thus, the anticonvulsant agent Depakote may have
some advantages when used for agitation and aggression in dementia residents due to its
lower rates of drug interactions and adverse effects in the dementia population. The
authors addressed the impact of Depakote on behavioral, mood, and cognitive measures
in NH dementia residents who had a history of behavior problems associated with
dementia. The researchers utilized pharmacy databases and MDS assessments to obtain
data for residents that were receiving Depakote for behavior problems related to
dementia. Some exclusions were applied, such as residents that were receiving Depakote
for seizures (i.e., the indication for which Depakote is FDA-approved). A total of 450
residents were identified with behavior problems related to dementia and receiving
Depakote, and MDS assessments indicated that Depakote reduced the frequency of
negative behaviors; expressions of verbal distress; indicators of sad, apathetic and
anxious appearance; and sleep cycle problems (Meinhold et al., 2005). In sum, the
authors found the use of Depakote for agitation and aggression in dementia residents was
effective, safe, and tolerable. They concluded Depakote might have multiple beneficial
effects in NH dementia residents with a history of dementia with behavioral problems.
Results further suggested that if Depakote were used as a secondary agent and started
earlier in treatment, it may have more beneficial effects.
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Disadvantages of Depakote Use in NH Dementia Residents
The aforementioned results are inconsistent with the results from Narayana et al.
(2014), who concluded that Depakote is not beneficial for BPSD management in that
Depakote does not improve BPSD symptoms and increases the frequency of side effects.
Also, Tariot et al. (2005) compared Depakote and placebo treatments in residents with
AD. The authors performed three randomized, double-blind, placebo-controlled clinical
trials in 153 NH residents with AD complicated by agitation, and out of those 153
residents, 78 were assigned placebo and 75 Depakote. The clinical trial was six weeks in
length, and Depakote dosages were increased every 3 days until the target dose was
reached. The authors reported that Depakote did not show benefit over placebo in
alleviating AD-associated agitation in NH residents. Primary and secondary measures of
behavior, using the Last Observation Carried Forward (LOCF) and Completer
approaches, showed consistent results. The authors further reported none of the earlier
placebo-controlled studies had proved Depakote was effective for agitation in NH
dementia residents. The Tariot et al. (2005) study was the largest to prospectively address
agitation as the primary outcome. Previous and subsequent literature regarding the use of
Depakote for managing agitation in NH dementia residents have reported similar
findings. Herrman et al. (2007) reached findings along the same lines, reporting Depakote
is ineffective for managing agitation in NH residents with AD and may be poorly
tolerated in this population. The authors of the 2007 study discussed similar previous
randomized controlled trials that also showed no statistically significant benefits of

26
Depakote on primary outcome measures, though it showed efficacy for some secondary
measures. The major limitations of this study were the small sample size and crossover
design, but despite these limitations, significant worsening of symptoms during Depakote
treatment was found.
Impact of Depakote Doses and Levels in NH Dementia Residents
Herrman et al. (2007) found that lower Depakote doses and slower titration
schedules could improve tolerability (i.e., longer Depakote treatment phases could prove
beneficial in managing agitation in NH residents with AD). Similarly, Tariot et al. (2005)
used Depakote doses and levels similar to those in previous trials (doses are typically
lower in AD residents versus in those with seizure disorders or mania in younger
populations). The authors found it highly unlikely that higher doses would have been
tolerated well enough to justify their use, and they could not conclude that a longer
treatment period would have been more effective.
Tolerability and Effectiveness of Depakote in NH Dementia Residents
Mizukami et al. (2010) addressed the negative impacts of BPSD and how they are
often managed using psychoactive medications, despite the mortality rate. The authors
emphasized the urgent need for safer BPSD treatment in dementia patients. The aim of
their study, similar to Tariot et al. (2005) and Herrman et al. (2007), who reported that
Depakote was ineffective for managing agitation in NH dementia residents, was to
examine the efficacy and tolerability of Depakote in patients with BPSD. The study
consisted of 110 dementia patients treated with Depakote for behavioral disturbances
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(excluding those with reversible causes of dementia or with a diagnosis other than
dementia [e.g., delusional disorder]). The authors reported that unsteady gait, sleepiness,
nausea, dizziness, and headache were experienced by 13 of the 110 residents, though
serum tests showed no abnormal findings. They also found that out of the 110 patients,
ten were very much improved, 42 much improved, 34 minimally improved, 21 had no
change, and three worsened (i.e., the very much or much improvement was observed in
52 out of the 110 patients). They observed some adverse effects such as
hallucinations/delusions (6/54), irritability/excitement (70/85), aggression/agitation
(29/43), insomnia/delirium (35/58), inappropriate/purposeless behaviors (11/40), and
other symptoms not specified (25/46). In contrast to Tariot et al. and Herrman et al., this
study revealed Depakote was effective in 47.3% of the patients with BPSD without
experiencing serious adverse effects. The researchers also found Depakote was effective
in managing irritability, aggression, and agitation while there was no effect on
hallucinations/delusions and inappropriate behaviors. The authors cited results from
previous studies that reported the effectiveness of Depakote against agitation and
aggression in dementia patients. In contrast, results from randomized controlled trials
have been inconsistent, indicating a need for further research into the impact of Depakote
on agitation and aggression. Porsteinsson (2006) also addressed the use of Depakote as an
intervention for BPSD, reporting results from four placebo-controlled trials and
concluding that none of the studies was sufficient to define clinical practice due to
conflicting, inconclusive results. The 2006 study reported that three of the four studies
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had suggested possible short-term efficacy, tolerability, and safety of Depakote for
agitation and some other neuropsychiatric symptoms associated with dementia patients;
in the fourth study, there were no demonstrated benefits of Depakote over placebo. The
author concluded further research is needed to determine optimal use of Depakote for the
treatment of BPSD and to see if there are any long-term benefits in using Depakote to
manage BPSD.
Dolder et al. (2012) reported that the use of anticonvulsants (of which Depakote is
the most commonly prescribed) had yielded inconsistent results in residents with
dementia. The authors reported that Depakote had been believed to produce symptomatic
improvements in dementia due to its actions on GABA and N-methyl-D-aspartate
(NMDA) receptors. They also reported that in vitro and in vivo studies have
demonstrated Depakote may have neuroprotective effects on AD due to numerous
potential mechanisms such as prevention of beta-amyloid aggregation, decreased betaamyloid and neuritic plaque production, and induction of neurogenesis. That is, Depakote
can have positive effects on certain brain functions and chemical reactions in AD
residents. In contrast, the researchers mentioned that Depakote is not usually
recommended in evidenced-based treatment guidelines and position statements for
dementia residents. The authors further discussed conflicting findings over the years
regarding the use of Depakote in dementia residents for agitation, reporting that older
reviews were based primarily on open-label and retrospective studies and usually ended
with positive statements regarding the use of Depakote in dementia residents. In contrast,
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they reported more recent reviews that indicated controlled trials did not primarily end
with positive conclusions. As in the Tariot et al. study, residents were institutionalized
and had a diagnosis of dementia, and all residents are receiving Depakote for a seizure
disorder, other medical related conditions, and MH diagnoses, were excluded from the
study. Also, residents that were admitted to NHs with other medical causes (e.g.,
delirium, medication withdrawal, intoxication) for their behavior disturbances were
excluded. The authors gathered the resident’s demographic, diagnostic, medication, and
drug-level data from resident charts. The objective of their study was to describe the
dosages of Depakote among residents admitted to a geriatric ward for dementia-related
behaviors. The researchers took several subjects into consideration, such as Depakote
dosages before admission (if applicable) and at discharge, Depakote serum level about
discharge dose, the weight of the resident, and if the resident was on any antipsychotics
or benzodiazepines. Twenty studies were included in the Dolder et al. review: 18 of the
studies examined the effects of Depakote on residents with psychosis or behaviors in
dementia; another study examined the effects of Depakote to prevent behaviors, and
another trial investigated the tolerability of Depakote. The average age of residents was
80, with a diagnosis of AD, and agitation and aggression were the most common
indications for Depakote use. The authors concluded Depakote might be beneficial in
some residents with dementia-associated agitation based primarily on lower doses of
Depakote being associated with symptomatic improvement. In contrast, they reported the
same range of Depakote serum levels had not shown significant behavioral improvement,
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leaving important questions unanswered. In sum, the researchers reported Depakote does
not seem to be beneficial in preventing behavioral symptoms and, also, can produce
problematic side effects in some residents with dementia.
Gareri et al. (2009) examined Depakote-induced delirium in an AD patient with
moderate cognitive impairment associated with behavioral disorders, including
aggression, agitation, and severe insomnia. They reported that, after an initial benefit, the
patient suddenly developed hyperactive delirium, including worsening of insomnia and
agitation, severe confusion, delusions, and visual hallucinations alternated to sedation.
The researchers reported that Depakote was immediately stopped and symptoms
continued for approximately a week, while another medication was introduced and was
successful after three more days. This 2009 case study addressed (a) the possible negative
effects of prescribing Depakote to AD patients to manage agitation and aggression and
(b) the importance of minimizing the use of and titrating psychoactive medications in
dementia patients.
Depakote on Delaying or Preventing the Start of Symptoms and Slowing Cognitive
Decline
Tariot et al. (2011) attempted to determine whether Depakote treatment could
delay or prevent the start of symptoms of agitation or psychosis. The study consisted of
313 individuals with moderate AD who had not yet experienced agitation or psychosis.
The researchers utilized a multicenter, randomized, double-blind, placebo-controlled trial
with flexible doses of Depakote. The study was conducted over 24 months, followed by a
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2-month period of single-blind placebo treatment. The authors reported a total of 122
residents (59 receiving Depakote and 63 receiving placebo) completed 24 months of
treatment; 42 (27 receiving Depakote and 15 receiving placebo) reached 24 months
having discontinued the medication; 150 reached month 26. They found that there was no
difference between groups in the manifestation of agitation or psychosis and that there
was no difference in groups in change on any secondary outcome. Results revealed the
Depakote group had higher rates of somnolence, gait disturbance, tremor, diarrhea, and
weakness; and 88% of the residents that underwent magnetic resonance imaging (MRI)
showed greater loss in hippocampal and whole-brain volume, accompanied by greater
ventricular expansion (Tariot et al., 2011). In conclusion, the authors found Depakote that
treatment did not delay the start of agitation or psychosis or slow cognitive or functional
decline in patients with moderate AD, and the medication was associated with significant
toxic effects.
Impact of Depakote on STM in NH Dementia Residents
When searching the databases listed at the beginning of this chapter, there was
little to be found on the impact of Depakote on STM, identifying a significant gap in the
literature. STM is described as the system that temporarily stores and manages
information that is necessary to complete complex cognitive tasks (Ai-Guo et al., 2015).
Richter et al., (2015) discussed the effects of person-centered care on psychoactive drug
use in NHs. The authors discussed the high rates of psychoactive medication use within
NHs: they reported recent data showing that 30% of German NH residents were on
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psychoactive medications, many for inappropriate reasons. One of the adverse effects
they mentioned is diminished cognitive function. Though they mentioned worsening of
cognitive functioning, their research did not specifically touch on the impact of Depakote
on STM.
Impact of Psychoactive Medication on Cognitive Function in NH AD Residents
Dharmarajan and Gunturu (2009) discussed the high rates of AD in NH residents
and the possible causes. They described AD as a common, acquired disorder that is
manifested as slow, progressive memory loss with at least one cognitive dysfunction
(aphasia, apraxia, agnosia, or executive dysfunction), resulting in impaired occupational
and social performance. The researchers mentioned the deterioration in cognition from
earlier levels must occur in the absence of delirium or other causes of dementia (e.g.,
Parkinson’s disease or vascular dementia). The researchers discussed (a) the use of
psychoactive medications, including Depakote, to manage agitation and difficult
behaviors in NH dementia residents and (b) the impact of the medication on cognitive
function. Similar to the Richter study, the authors of the 2009 study touched lightly on
adverse effects and cognitive functioning but not specifically on STM.
Case Study on the Negative Impact of Depakote
Manckoundia et al. (2008) did a case study of a 68-year-old woman who
developed dementia symptoms after starting Depakote for seizures. Before starting
Depakote, the woman did not have any neurological complications, but after several
months of Depakote use, she presented with a decline in cognitive function and
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withdrawal from social activities. The authors reported that her psychological assessment
revealed memory difficulties, predominantly STM with impairment of recall memory,
disorientation to time, and difficulty finding words and writing. Her mini-mental
(MMSE) score was 15, and discrete lesions were evident on an MRI. The researchers
believed Depakote was the possible cause of the woman’s psychomotor slowing. After
Depakote was discontinued, the woman experienced rapid clinical and objective
improvement, and three weeks after stopping Depakote, her psychomotor slowing had
resolved; her speech was normal; her MMSE score was 25, and she started engaging in
social activities again. This case study indicated that Depakote had a negative impact on
short-term memory and when discontinued, STM returned to baseline.
Impact of Mood Stabilizers on Cognitive Functioning
Dutcher et al. (2014) researched exposure to medications (such as Depakote)
commonly used in NH dementia residents. The authors reported that slower cognitive
decline was associated with antidepressants and antipsychotics, but poorer outcomes
were observed with mood stabilizers, such as Depakote. The study was a 2-year
longitudinal investigation of 18,950 NH residents who were newly diagnosed with
dementia and resided in the NH for at least part of the two-year study period. The authors
obtained their data from the Chronic Conditions Data Warehouse (CCW) and nursing
home MDS records. Their study included residents’ exposure to four classes of
medications: antidementia medications (ADMs), antipsychotics, antidepressants, and
mood stabilizers. Outcomes included the performance of ADLs and cognition using
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Cognitive Performance Scale (CPS). Study results indicated ADM was not associated
with a change in ADLs over time but was associated with a slower CPS decline;
antidepressant use was associated with slower declines in ADLs and CPS. They reported
that sex modified the effect of both antipsychotic and mood stabilizer use on ADLs;
female users declined more quickly than males. They also reported that antipsychotic use
was associated with slower CPS decline, whereas mood stabilizer use had no effect (i.e.,
Depakote did not have any effect on slower CPS decline). The authors reported that
despite the statistically significantly slower declines in cognition with ADMs,
antidepressants, and antipsychotics and the slower ADL decline found with
antidepressants, it is unlikely that these benefits are of clinical significance.
Possible Benefits in Cognitive Functioning with Depakote Use
A study by Ai-Guo et al. (2015) using mice looked at how astrocytes and
microglia activated by amyloid-β (Aβ) contribute to the inflammatory process that
develops around an injury in the brain. The authors reported that Depakote had been
shown to have an anti-inflammatory function, and their study looked to explore the
therapeutic effect of Depakote on the neuropathology and memory deficits in transgenic
mice. They reported mice treated with Depakote showed markedly improved memory
deficits and decreased Aβ deposition compared with the non-Depakote treated mice.
Also, the extensive astrogliosis and microgliosis, as well as the increased expression in
interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the hippocampus and
cortex of the transgenic mice, were significantly reduced after Depakote, which lessened
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neuronal degeneration. Simultaneously, Depakote alleviated the levels of p65 NF-kB
phosphorylation and enhanced the levels of acetyl-H3, Bc1-2, and phosphoglycogen
synthase kinase (GSK)-3β that occurred in the hippocampus of the transgenic mice.
These results indicate that Depakote could significantly improve spatial memory
impairment and Aβ deposition, at least about inflammation. The researchers described
spatial memory as being the part of the memory responsible for recording information
regarding the environment and spatial orientation, and about STM, the spatial memory
includes tasks such as learning, reasoning, and comprehension. Similarly, Yao et al.
(2014) described AD as a very common progressive neurodegenerative disorder that
affects learning and memory abilities in the brain. The researchers discussed key findings
from recent studies of epigenetic mechanisms of memory that suggests chromatin
remodeling disorders via histone hypoacetylation of the lysine residue contribute to the
cognitive impairment in AD. These findings indicate that the inhibition of histone
acetylation induced by histone deacetylases (HDACs) inhibitors contributes to the
recovery of learning memory. This, in turn, indicates it is possible for STM to ameliorate
during Depakote use. As in the Ai-Guo et al. study, Yao et al. looked at various
mechanisms that could significantly change brain functioning in transgenic mice. They
discussed how Depakote enhanced long-term recognition memory and spatial learning
and memory in AD transgenic mice. Their research showed that Depakote could
significantly elevate histone acetylation through HDACs activity inhibition and increase
plasticity-associated gene expression within the hippocampi of mice. In sum, their study
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suggested Depakote, when serving as an HDAC inhibitor, can be considered as a
potential psychoactive medication for the improvement of cognitive function in AD.
Furthermore, this research points up the gap in and need for research on the impact of
Depakote on STM in NH dementia residents, as existing studies continue to yield
inconsistent results.
Summary and Conclusions
This chapter provided a detailed account of current professional literature about
the impact of Depakote on agitation and STM in NH dementia residents. A considerable
number of studies have focused on various aspects of Depakote, agitation, and STM,
including risks versus benefits, the effectiveness of psychoactive medications, and how
the use of psychoactive medications might modify already present psychiatric symptoms.
Depakote uses to manage BPSD in NH dementia residents was consistently reported not
to improve agitation in dementia and to increase the frequency of side effects (Narayana
et al., 2014). Although Depakote treatment options exist to treat agitation in NH dementia
residents, inconsistent findings from existing research studies indicate the need for further
research on the use of Depakote to manage agitation and aggression in BPSD in NH
residents. Additionally, research studies considered the potential for a decline in
cognitive function among NH residents with AD while on Depakote but did not touch
specifically on STM in NH residents with AD. Several studies in the literature review
conducted research addressing exposure to psychoactive medications and cognitive
function (Dutcher et al., 2014; Ai-Guo et al., 2015; Yao et al., 2014).
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Again, due to inconsistencies in findings from the literature reviewed, there is a
continued call for further research into the impact of Depakote on agitation and STM in
NH dementia residents. The impact of Depakote on agitation and STM in NH residents
with dementia remains unclear. The goal of this study was not to solve the identified
problem but to add to the existing literature, thereby increasing knowledge on the impact
of Depakote treatment on agitation and STM in NH dementia residents over a 1-year
period. Chapter 3 lays the groundwork for the research design, methodology, and data
collection procedures used to complete this study.
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Chapter 3: Research Method
The purpose of this quantitative study, which included a nonexperimental design,
was to examine the impact of Depakote on agitation and STM in NH residents with
dementia over a 1-year period. The independent variable was Depakote treatment, and the
dependent variables were agitation and STM. There was also a variable of interest, effect
over time (trials). The study included a confounding variable, which was the residents’
original Depakote start date to test for within-subject effects.
This chapter contains the research methods employed in this study. A brief review
of the design and rationale of the study, including setting and sampling procedure,
procedures for recruitment, participation and data collection, and instrumentation, is
presented. Next, the data analysis plan is discussed, including research questions,
hypotheses, and statistical tests. A review of the threats to external, internal, and
construct validity, including reliability of the instrument, data assumptions, sample size,
and the measures taken to protect residents’ rights, concludes this chapter.
The independent variable for this study was Depakote treatment, and the
dependent variables were agitation and STM. According to the Diagnostic and Statistical
Manual of Mental Disorders (DSM-5, 2013), agitation and memory loss are two
symptoms of dementia. Resident behaviors, psychological symptoms, and cognition were
examined to determine whether Depakote use impacted agitation and STM. The residents
in this study were required to have a diagnosis of dementia and be prescribed Depakote
for BPSD from their medical doctor or psychiatrist. Any residents receiving Depakote to

39
treat seizure disorder were excluded from this study (FDA, 2010). All data for this study
were archived data from an existing dataset, and there was no direct communication
between me and the residents.
This chapter presents a detailed description of the methodology used in this study
to facilitate replication by other researchers. The major sections include the sampling and
sampling procedures along with all procedures of recruitment, participation, and data
collection. Next, I describe the instrument and operationalization constructs including the
developers, appropriateness to this study, and reliability and validity. Additionally,
threats to validity such as external, internal, and construct validity are presented. Finally,
ethical procedures and concerns related to this study are described.
Research Design and Rationale
This quantitative study included a nonexperimental design. Data for sample
selection were collected data using consulting pharmacy records. Data were then
measured by MDS assessment results to determine whether Depakote use affected levels
of agitation and STM in NH dementia residents over a 1-year period.
I used a quantitative approach including a repeated-measures within-subjects
ANOVA to analyze data from two archived databases containing NH residents receiving
Depakote. Because the purpose of this study was to determine whether Depakote
impacted levels of agitation and STM over a 1-year period, a repeated-measures withinsubject (effect over time) design was appropriate for this study. The repeated-measures
design facilitated testing the null hypothesis and the alternative hypothesis, and all
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archived data were measured on each variable. The null hypothesis stated there are no
statistically significant differences in levels of agitation or STM in the Depakote
treatment group over a 1-year period. The alternative hypothesis stated there are
statistically significant differences in levels of agitation and STM in the Depakote
treatment group over a 1-year period.
Because I used archival data from two existing data sets, I did not have direct
contact with the residents, which mitigated ethical issues related to vulnerable
populations and cognitively impaired residents. Data were gathered from the consulting
pharmacies’ database and two NHs MDS records to measure the impact of Depakote use
on agitation and STM in NH dementia residents. This system of data gathering ensured
the diagnosis of dementia, prior behaviors, current behaviors, and resident receipt of
Depakote over the 1-year period. MDS is a tool mandated for use in NHs for clinical
assessments of all residents on Medicare and Medicaid. The MDS provides a
comprehensive assessment of each resident’s functional capabilities, health-related
issues, behaviors, psychological symptoms, and cognitive function.
Methodology
Population
The target population for this study was dementia residents from two local NHs.
The residents for this study consisted of NH dementia residents receiving Depakote
treatment for BPSD from January 1, 2016, through December 31, 2016, because this was
the most recent data representing a full calendar year.
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Sampling and Sampling Procedures
Purposive sampling was used for this study because the NH sample was being
sampled with a specific purpose (specific to NH residents on Depakote and its impact on
agitation and STM; see Frankfort-Nachmias, Nachmias, & DeWaard, 2015). Purposive
sampling is a nonprobability technique that was used based on characteristics of the NH
dementia residents (population) and Depakote treatment (objective). This sampling
strategy was suitable for this study’s research questions and variables addressing the
extent to which Depakote impacts agitation and STM in NH dementia residents over a 1year period.
The sample for this study was obtained from archival data collected from January
1, 2016, through December 31, 2016, by the consulting pharmacy and the NHs MDSs.
The procedure for drawing the sample involved various steps. First, all residents were
from the two local NHs and were receiving Depakote for BPSD. Second, the consulting
pharmacy records were provided with deidentified data including psychoactive
medications, the reason for Depakote prescription, Depakote dosage, and the start date of
Depakote administration. Residents receiving Depakote for any reason other than
agitation/behaviors related to dementia were excluded. Also, residents were required to
be on Depakote for the entire 1-year period. Third, MDS records were obtained through
the NHs. MDS records included deidentified data including date of birth, gender, and
Sections C (Cognitive) and E (Behavioral) of the MDS. The consulting pharmacy and
NHs are the owners of the data, so permission was not needed from the residents. Data
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agreements between the data providers and me ensured protection and confidentiality of
resident information.
The study’s sampling frame was the group of residents from two local NHs that
met eligibility criteria for selection. More specifically, the sampling frame was the
consulting pharmacy list of NH residents receiving Depakote, comprising the sample
selection of MDSs from the two NHs (permission granted through data agreements
between the data providers and me). Only residents on Depakote for behaviors/agitation
from that list met study selection criteria. Any NH resident on Depakote for any other
reason other than BPSD was excluded from the study because the study was specific to
dementia residents. Moreover, only selected data collected from those residents who had
been receiving Depakote for the entire 1-year period were used. Gender, race, and age
were not examined in this study because of the smaller sample size.
The sample size of a study is determined before research begins as an effort to
ensure a sufficient number of responses (Creswell, 2014). Having a sufficient sample size
ensures enough data (Creswell, 2014). I used G*Power 3.1 (see Faul, Erdfelder, Buchner,
& Lang, 2009) to calculate sample size for a one-way repeated-measures ANOVA. When
a population is of limited size, Cohen (1982) stated it is appropriate to set the alpha at .10
or higher, and Stevens (2002) stated a priori power should be at least .70. With four
repeated measures correlated at .50, a medium-size population effect size of Cohen’s f =
.25 would be detectable with a sample size of 15, and an even smaller effect size of
Cohen’s f = .20 would be statistically significant within the sample.
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Procedures for Recruitment, Participation, and Data Collection
Resident data were data archived from January 1, 2016, to December 31, 2016,
from two local NHs. At the beginning of this research process, I contacted both NH
administrators face-to-face to introduce the study, explain the purpose of the study, and
request use of residents’ MDS archival data. Immediate approval was given by both NH
administrators at that time to obtain residents’ MDS data for this study. Next, I contacted
the pharmacy consultant via e-mail to introduce the study. I explained the purpose of the
study and requested archival data (i.e., residents on Depakote, Depakote administration
start and end dates, the reason for Depakote use, gender, and date of birth). The pharmacy
consultant agreed to provide the requested data for this study.
The data collection for the main dataset required the consulting pharmacy to
provide data from residents of two local NHs who are on Depakote treatment for BPSD.
The consulting pharmacy has proprietary rights to all the de-identified information that
was provided. The procedure for gaining access to the data set involved a data use
agreement between the data provider (consulting pharmacy) and the data recipient (me),
which permitted limited use of the de-identified data set for research purposes only. The
data use agreement (Appendix A) with the consulting pharmacy specified access to a
limited deidentified data set (i.e., date of birth, gender, psychoactive medications, the
reason for Depakote prescription, the dosage of Depakote, and the start date of Depakote
administration).
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Collection of secondary data involved administrators and MDS coordinators from
both participating NHs. NH administrators authorized NH MDS coordinators to give
access to MDS records of study residents from the main data set. NH MDS coordinators
provided copies of study residents’ Sections C (Cognitive) and E (Behavioral) of the
MDS (deidentified dataset). NHs have the sole rights to all MDS records needed for this
study; therefore, resident permission was not needed. The procedure for gaining access to
the data set involved a data use agreement similar to the agreement with the consulting
pharmacy. The data use agreement was between the data provider (NH) and data
recipient (me), which permitted limited use of the de-identified data set for research
purposes only. The data use agreement with the NHs specified a limited data set (i.e.,
date of birth, gender, and Sections C [Cognitive] and E [Behavioral] of the MDS).
Use of the data sets was granted from the consulting pharmacy and the two local
NHs (i.e., the owners of the confidential data being provided to me). All residents had a
diagnosis of dementia and were not able to provide consent; therefore, the NHs had the
right to determine the utility of sharing the data for research purposes. Residents were
identified by ID 1-16, and NH names remained confidential to protect all information
shared for this study. These data were inputted into R Statistical Software for statistical
analysis.
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Instrumentation and Operationalization of Constructs
Minimum Data Set (MDS)
The MDS is a standardized tool for assessment and facilitation of care
management in NHs developed by U.S. Centers for Medicare & Medicaid Services
(CMS; CMS.gov, 2015). The MDS is a care management tool used in NHs and is a set of
screening and assessment tools that are part of a Resident Assessment Instrument (Cirillo,
2017). The MDS provides an assessment of NH residents’ functional capabilities and
helps identify problem areas. The MDS is performed on every resident in Medicare
and/or Medicaid-certified long-term care facilities.
The MDS is designed to be reliable and accurate and to include the resident (if
cognitively able) in the assessment process. CMS (2015) reported that enhanced accuracy
of the MDS supports the intent that MDS be a tool to improve clinical assessment and
support the credibility of programs that rely on MDS. The MDS includes frequency
reports designed to summarize each NH resident’s information, creating an MDS
assessment record. The MDS assessment information for each NH resident is
consolidated to create a profile of the most current standard information for the resident.
A detailed copy of Sections C (Cognitive) and E (Behavioral) of the MDS is located in
Appendix D.
The MDS is structured by sections A-Q, V, X, and Z, including a title and intent
for each section. Each section provides instructions on how to complete the section. The
MDS consists of the following areas: functional, physical, psychological, and health.
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Section titles are as follows: Identification Information (A), Hearing, Speech, and Vision
(B), Cognitive Patterns (C), Mood, Behavior (D), Preferences for Customary Routine and
Activities (F), Functional Status (G), Bladder and Bowel (H), Active Disease Diagnosis
(I), Health Conditions (J), Swallowing/Nutritional Status (K), Oral/Dental Status (L),
Skin Conditions (M), Medications (N), Special Treatments and Procedures (O),
Restraints (P), Participation in Assessment and Goal Setting (Q), Care Area Assessment
(CAA) Summary (V), Correction Request (X), Assessment Administration (Z).
An example is from Section C, Cognitive Patterns. This area begins with C0100:
Should Brief Interview for Mental Status (C0200-C0500) be conducted? This interview
should be attempted with all residents. This area is coded as follows: (0) No (resident is
rarely/never understood)–Skip to and complete C0700-C1000, Staff Assessment for
Mental Status, (1) Yes–Continue to C0200, Repetition of Three Words. For example, if
the response were coded 1, the next section would be Brief Interview for Mental Status
(BIMS) (C0200) Repetition of Three Words. The resident is asked to repeat three words,
for example, sock, blue, and bed. This area is coded by the number of words repeated
after the first attempt: (0) None, (1) One, (2) Two, (3) Three. After the resident’s first
attempt, the examiner repeats the words using cues such as sock, something you wear;
blue, a color; bed, a piece of furniture, and these words may be repeated up to two more
times. Followed by Temporal Orientation (C0300) (orientation to year, month, and day).
(A) Able to report correct year is coded (0) Missed by > 5 years or no answer, (1) Missed
by 2-5 years, (2) Missed by 1 year, (3) Correct; (B) Able to report correct month is coded
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(0) Missed by >1 month or no answer, (1) Missed by 6 days to a month, (2) Accurate
within 5 days; (C) Able to report correct day of the week is coded (0) Incorrect or no
answer, (1) Correct (CMS.gov, 2015). Followed by Recall (C0400) (Ask resident to
repeat the three words asked earlier). (A) Able to recall “sock”, (B) Able to recall “blue,”
(C) Able to recall “bed,” all coded using (0) No, could not recall, (1) Yes, after cueing,
(2) Yes, no cue required (CMS.gov, 2015).
At this point in the assessment, scores are added up from sections C0200-C0400,
ranging from 00-15 (15 being the most cognitively intact). The assessor would enter 99 if
the resident was unable to complete the interview.
If the resident was unable to complete the interview, a staff assessment is
completed. This area begins with C0600, Should Staff Assessment for Mental Status be
Conducted? This area is coded (0) No (resident was able to complete interview) Skip to
C1300, Signs, and Symptoms of Delirium, (1) Yes (resident was unable to complete
interview) Continue to C0700, Short-term Memory OK. Staff Assessment for Mental
Status (C0700) Short-term Memory OK (seems or appears to recall after 5 minutes) is
coded (0) Memory OK, (1) Memory problem, (C0800) Long-term Memory OK (Seems
or appears to recall long past) is coded (0) Memory OK, (1) Memory problem, (C0900)
Memory/Recall Ability (check all that resident was normally able to recall) is coded (A)
Current season, (B) Location of own room, (C) Staff names and faces, (D) That he or she
is in a nursing home, (Z) None of the above were recalled. Followed by Cognitive Skills
for Daily Decision Making (C1000) (Made decisions regarding tasks of daily life) is
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coded (0) Independent—decisions consistent/reasonable, (1) Modified independence—
some difficulty in new situations only, (2) Moderately impaired—decisions poor;
cues/supervision required, (3) Severely impaired—never/rarely made decisions
(CMS.gov, 2015).
The next area is Delirium (C1300) Signs and Symptoms of Delirium. (A)
Inattention, (B) Disorganized thinking, (C) Altered level of consciousness, (D)
Psychomotor retardation, all of which are coded using (0) Behavior not present, (1)
Behavior continuously present, does not fluctuate, (2) Behavior present, fluctuates
(comes and goes, changes in severity). Lastly in the cognitive section, is Acute Onset
Mental Status Change (C1600), Is there evidence of an acute change in mental status
from the resident’s baseline?. This area is coded (0) No, (1) Yes (CMS.gov, 2015).
Another example is from Section E, Behavior, (E0100) Psychosis (Check all that
apply) (A) Hallucinations (perceptual experiences in the absence of real external sensory
stimuli), (B) Delusions (misconceptions or beliefs that are firmly held, contrary to
reality), (Z) None of the above. Followed by Behavioral Symptom—Presence and
Frequency (E0200), (A) Physical, behavioral symptoms directed toward others (hitting,
kicking, pushing, scratching, grabbing, abusing others sexually), (B) Verbal behavioral
symptoms directed toward others (threatening others, screaming at others, cursing at
others), (C) Other behavioral symptoms not directed toward others (physical symptoms
such as hitting or scratching self, pacing, rummaging, public sexual acts, disrobing in
public, throwing or smearing food or bodily wastes, or verbal/vocal symptoms like
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screaming, disruptive sounds). This area is coded using the following: (0) Behavior not
exhibited, (1) Behavior of this type occurred 1 to 3 days, (2) Behavior of this type
occurred 4 to 6 days, but less than daily, (3) Behavior of this type occurred daily. Overall
Presence of Behavioral Symptoms (E0300), Were any behavioral symptoms in questions
E0200 coded 1, 2, or 3? (0) No—skip to E0800, Rejection of care, (1) Yes—Considering
all of E0200, Behavioral Symptoms, answer E0500 and E0600. Impact on Resident
(E0500), Did any of the identifying symptom(s): (A) Put the resident at significant risk
for physical illness or injury, (B) Significantly interfere with the resident’s care, (C)
Significantly interfere with the resident’s participation in activities or social interactions,
all coded with (0) No or (1) Yes. Impact on others, (E0600), Did any of the identifying
symptom(s): (A) Put others at significant risk for injury, (B) Significantly intrude on the
privacy or activities of others, (C) Significantly disrupt care or living environment, all
coded with (0) No or (1) Yes (CMS.gov, 2015).
Rejection of Care—Presence and Frequency (E0800), Did the resident reject
evaluation or care (bloodwork, taking medications, ADL assistance) that is necessary to
achieve the resident’s goals for health and well-being (excluding already addressed
behaviors): (0) Behavior not exhibited, (1) Behavior of this type occurred 1 to 3 days, (2)
Behavior of this type occurred 4 to 6 days, but less than daily, (3) Behavior of this type
occurred daily (CMS.gov, 2015).
Wandering—Presence and Frequency (E0900), Has the resident wandered: (0)
Behavior not exhibited, (1) Behavior of this type occurred 1 to 3 days, (2) Behavior of
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this type occurred 4 to 6 days, but not daily, (3) Behavior of this type occurred daily.
Wandering—Impact (E1000): (A) Does the wandering place the resident at significant of
getting to a potentially dangerous place (stairs, outside of the facility), (B) Does the
wandering significantly intrude on the privacy or activities of others, all coded (0) No or
(1) Yes. Finally, to sum up the behavior section E, Changes in Behavior or Other
Symptoms (E1100), How does resident’s current behavior status, care rejection, or
wandering compare to prior assessment, coded as (0) Same, (1) Improved, (2) Worse, (3)
N/A because no prior MDS assessment (CMS.gov, 2015).
The MDS includes reports for statistical and comparison purposes, such as
Facility Characteristics Report, Facility Level Quality Measure Report, Resident Level
Quality Measure Report, Monthly Comparison Report, and Quality Measures Reports
versus Nursing Home Compare. These reports provide NHs with the statistical data
gathered from their facilities as well as facilities in their same state and other states for
comparison purposes. For example, when an NH is rated by a number of stars, the MDS
reports will provide the NH with knowledge of the areas that their facility lacks in
compared to other facilities. This will help improve quality of care. Also, the MDS
reports specify areas for improvement. Tucker (2013) reported that research over the past
four years, since the MDS was restructured, has shown an increase in reliability and
validity, specifically inaccuracy of the mood and cognitive status sections. One of the
main components of this improvement is involving the NH residents (if cognitively able)

51
and/or direct care staff in the assessments, which provides more accurate and valid
responses.
Data Analysis Plan
This study was conducted using R statistical software version 3.3.1 to examine to
what extent Depakote affects levels of agitation and STM in NH dementia residents over
a 1-year period. These variables were measured using the consulting pharmacy’s records
and two NH MDS records in four intervals over a 1-year period and imputed into R
statistical software for statistical analysis. A repeated measures ANOVA was used to
analyze data in R statistical software. Additionally, boxplots were done to examine if the
length of time the resident was on Depakote had any significance on resident’s agitation
and STM scores.
Restatement of the Research Questions and Hypotheses
RQ1: To what extent does Depakote treatment affect levels of agitation in NH
dementia residents over a 1-year period?
H01: There is not a statistically significant difference in levels of agitation with
Depakote treatment over a 1-year period as evidenced by no change in agitation from
preexisting data in Section E of the MDS.
Ha1: There is a statistically significant difference in levels of agitation with
Depakote treatment over a 1-year period as evidenced by decreased agitation from
preexisting data in Section E of MDS.
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RQ2: To what extent does Depakote treatment affect STM in NH dementia
residents over a 1-year period?
H02: There is not a statistically significant difference in STM with Depakote
treatment over a 1-year period as evidenced by no change in STM functioning from
preexisting data in Section C of the MDS.
Ha2: There is a statistically significant difference in STM with Depakote
treatment over a 1-year period as evidenced by decreased STM functioning from
preexisting data in Section C of MDS.
Statistical Testing
This study used a repeated measures ANOVA statistical test that screens for
multiple measures from a group of people (Frankfort-Nachmias, Nachmias, DeWaard,
2015). A repeated measures ANOVA is used when there are multiple dependent
variables, and the researcher is looking for differences amongst treatment groups.
Therefore, since this study consisted of two dependent variables (agitation and STM), one
independent variable (Depakote treatment group), and repeated measures within factor
(effect over time) using four intervals over a 1-year period, the data were screened using
a repeated measures ANOVA to test the null and alternative hypotheses. Hence, the
ANOVA statistical analysis was appropriate to examine to what extent Depakote affected
levels of agitation and STM in the Depakote treatment group. Additionally, ANOVA was
used to consider a within factor effect over time, which was pertinent to testing this
study’s hypothesis and provided adequate statistical power. The study included a
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confounding variable, which was the residents’ original Depakote start date, to test for
within-subject random effects. Hence, box plots were employed for comparison of a
number of months the resident was on Depakote before the study. Further, the results of
this study were interpreted using certain key parameter estimates.
Threats to Statistical Conclusion and Validity
External Validity
External validity refers to a generalization of the treatment outcomes. For
example, the external validity in this study related to repeated measures as it is difficult to
control for the effects of prior outcomes using the same subject (Frankfort-Nachmias,
Nachmias, & DeWaard, 2015). A repeated measures ANOVA was used for this study
because it allows both dependent variables to be measured on the same independent
variable. Also, this study had a within-subject variable of interest (effect over time) to
examine if the residents changed from the first trial to final trial, which minimized threats
to external validity. No pretest was conducted which could have potentially influenced
the residents’ responsiveness or sensitivity to the experimental variable (Creswell, 2014),
thereby resulting in no threats to a reactive or interaction effect of testing for this study.
Also, there were no threats of multiple treatment interferences (no multiple treatments
will be given to the same subject). Reactive effects of experimental arrangements for
effects are nonexperimental and can be easily generalized.
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Internal Validity
The internal validity of a study refers to whether results of the study can be used
to determine (a) if treatment makes a difference or not and (b) if there is sufficient
evidence to support the claim (Creswell, 2014; Frankfort-Nachmias, Nachmias, &
DeWaard, 2015). In this study, a repeated measures ANOVA was used to determine the
impact of Depakote on agitation and STM. There was a possibility this design could
increase the chances of internal validity by testing both dependent variables (representing
different measurements) against the same independent variable. However, there are
always factors that can jeopardize internal validity. For example, if the scorer of the MDS
changes, there is a possibility of outcome changes. Furthermore, about the threats above
to internal validity, the instrument (MDS) for this study was designed to be a reliable tool
for clinical assessments (CMS.gov, 2015).
Construct Validity
Construct validity refers to how well a test or tool measures the theorized
psychological construct it was designed to measure (Cronbach & Meehl, 1955). The tool
used in this study, the MDS, was designed to measure agitation/behaviors and cognition.
This study was not exposed to construct validity, such as hypothesis guessing by
residents, bias experimental design, and researcher expectations (secondary data was
used; Cronbach & Meehl, 1955). However, this study may have been exposed to a threat
to the construct validity in that it was difficult (a) to establish disease-specific actions and
(b) to distinguish whether outcomes occurred because of the medication’s actions on an
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underlying pathological process or as a consequence of being in an altered state
(Moncrieff & Cohen, 2009). Those above was identified in the limitation section. This
potential limitation is an area for further research.
Ethical Procedures
Protection of Residents’ Rights
Ethical behaviors and protection of this studies residents are a serious matter for
psychological studies. Every action in this study was taken with careful consideration for
the residents. Agreement to gain access to the consulting pharmacists’ data was received
by way of a formal data use agreement (see Appendix A). The agreement was signed by
both the data provider and data recipient to permit the usage of the dataset from the
consulting pharmacist. The agreement was limited to the resident’s gender, date of birth,
psychoactive medications, the reason for Depakote prescription, Depakote dosage level,
and the start date of Depakote. The contract excluded all medications other than
psychoactive medications. A detailed copy of the data use agreement contract is located
in Appendix A.
Access to the NHs MDS records was gained by way of formal data use
agreements (see Appendices B and C). The agreements were signed by both NHs (data
providers) and the data recipient to permit usage of the MDS dataset. The agreements
were limited to the resident’s date of birth, gender, and Sections C (Cognitive) and E
(Behavioral) of the MDS. The contracts excluded all identifying information. Detailed
copies of the data use agreement contracts are located in Appendices A-C.
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This study did not involve any interactions with or observations of human
subjects. Permission was gained from the Institutional Review Board (IRB) by
completing an application to ensure that the ethical principles of beneficence, justice, and
respect for persons were upheld in this study. In this study, secondary data were used,
thereby limiting ethical concerns related to recruitment materials and processes as well as
data collection. In the collection of the original data, the collectors of the data, the
consulting pharmacist and two local NHs, ensured that residents were treated fairly.
Confidentiality and limits to confidentiality were discussed and guaranteed in the original
data collection process. Furthermore, families of the residents were involved in making a
choice regarding psychoactive medications, including risks and benefits. There were no
reports of families declining the administration of psychoactive medications or any
adverse events that occurred during the original data collection process. There was also
no report of any resident’s Depakote being discontinued during the 1-year study period.
Data are confidential as stated in the resident’s initial paperwork upon admission
to the NHs. Before starting psychoactive medications, the NHs notify the resident and/or
families of their consent. There have been no breaches of confidentiality or concerns
about this data set.
The pharmacy consultant and the NHs abide by strict measures to preserve the
confidentiality of the data. The procedure involved no access to data from the pharmacy
consultant other than for the NHs purpose. The pharmacy consultant stored resident data
securely on his computer. Additionally, the NHs abide by strict measures to preserve the
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confidentiality of the data. MDSs are stored on computers of clinical staff that complete
them, in the MDS 3.0 software program. Both data providers back data up on discs for
safety purposes in the event that computers crash.
The data dissemination of the pharmacy consultant was limited to himself, both
NHs, and the pharmacy that dispenses the medications. The data dissemination of the NH
MDS’s was limited to the NHs, insurance companies (for payment purposes), and the
New York State Department of Health (NYSDOH) to ensure proper completion and
adherence. The residents and/or families were not recipients of the reports or data. In
compliance with NYSDOH guidelines, an NH resident’s data are held for seven years
following the resident’s death.
Hard copies of data received from the pharmacy consultant and the NHs are
secure in a locked fireproof box, and the researcher is the only person with access to that
locked box. The raw data were coded into R statistical software for statistical analysis,
using my personally secured (administrator password-protected) computer equipped with
Webroot antivirus software and anti-spyware protection. Following analysis, statistical
data were then securely stored on a separate hard drive with restricted access by
administrator password protection. Also, write permission was disabled to prevent
altering of the data so that they remained safe. Antivirus and anti-spyware were run on a
daily basis and updates were applied to maintain the security of the data set. Lastly, the
data will be kept for five years as required by Walden University, and copies will be
stored in two different locations (Walden University, 2014). After the five-year period,
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the data will be securely shredded and disposed of, and electronic files will be erased
from computers.
There are no other ethical issues related to this study. Using secondary data
eliminated the ethical risk of conducting the study at my internship site, eliminating
conflicts of interest in this study. Also, use of secondary data protects both the vulnerable
population (geriatric NH residents) and me from ethical risks.
Summary
This chapter included justification for the research design and rationale for my use
of a quantitative approach with repeated measures within-subject design to analyze
archival data. The rationale for the use of a repeated measures ANOVA was discussed. It
was agreed that a repeated measures design for this study facilitated testing the
hypotheses of whether or not there is a statistically significant difference in levels of
agitation and STM with Depakote treatment over a 1-year period. Moreover, effect over
time was a variable of interest that measured if the residents changed from the first trial to
the final trial. The methodology, including the target population (local NH dementia
residents) sampling strategy (purposive sampling), procedures, sampling frame, and
power analysis were used to determine sample size and discussed in depth to ensure that
this study was replicable. Next, the data collection procedures of the archival data along
with the published instrument (MDS) were presented. Further, the threats to the study’s
external, internal, and construct validity were examined, as well as how these threats
were addressed and presented. Finally, ethical procedures including data agreements (i.e.,
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what data will be included in the data set provided), treatment of human residents (with
beneficence, justice, and respect), and treatment of data (with confidentiality maintained
and protected) were examined and addressed. The subsequent chapter will explore the
analysis of the data set, the study’s findings, and a summary of the answers to the
research questions.
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Chapter 4: Results
The purpose of this nonexperimental quantitative study was to examine the
impact of Depakote on agitation and STM in NH dementia residents over a 1-year period.
This study was conducted to answer two research questions:
1. To what extent does Depakote treatment affect levels of agitation in NH
dementia residents over a 1-year period?
2. To what extent does Depakote treatment affect STM in NH dementia
residents over a 1-year period?
The first null hypothesis stated no statistically significant difference in levels of agitation
with Depakote treatment over a 1-year period as evidenced by no change in agitation
from preexisting data in Section E of the MDS. The second hypothesis stated no
statistically significant difference in STM with Depakote treatment over a 1-year period
as evidenced by no change in STM functioning from preexisting data in Section C of the
MDS. The hypotheses were tested using repeated-measures ANOVA. This chapter
presents the method for collecting data and the results of the data analysis to address the
research questions and hypotheses. First, I provide the details of the data collection,
including descriptive statistics of the sample. Then I present the results of the data
analysis. This chapter concludes with a summary of findings.
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Data Collection and Characteristics of the Sample
Data Collection
NH residents with dementia and agitation who were receiving Depakote over the
1-year period were the sample for this study. A total of 16 residents from the two NHs
were used for the sample. Two NHs were necessary to obtain the required sample size
based on selection criteria that residents had been on Depakote for the 1-year period, had
been diagnosed with dementia, had been prescribed Depakote to treat agitation, had not
been prescribed Depakote for other diagnoses. A sample from one facility was too small
for the study, and a second facility was needed. There were no variations between the two
NH MDS data sets because both NH MDS coordinators were expected to follow the same
MDS completion requirements. Demographics were not included in this study because
the sample was too small for demographics to be significant (see Cohen, 1982). Data
from the consulting pharmacy providing residents who met the study criteria were sent
via secured e-mail to the participating NH data providers following IRB approval. I
obtained study data within three days of the NH receiving the data from the consulting
pharmacy. I physically acquired all residents’ MDSs from the data providers, which
included four separate MDSs per resident for repeated measures during the study period.
This data collection process went as proposed and there were no discrepancies.
Characteristics of Sample
All residents were residents at one of the two participating NHs, had a diagnosis
of dementia, and were receiving Depakote over the 1-year period. Their Depakote start
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dates varied from 2013 through 2016, but they were all receiving Depakote from January
2016 through December 2016, which was the period evaluated. Each resident had four
measures of agitation and STM scores over the 1-year period. Possible behavior/agitation
scores ranged from 0 to 3, 0 indicating no behavior exhibited, 1 indicating behavior
occurred 1 to 3 days, 2 indicating behavior occurred 4 to 6 days (but less than daily), and
3 indicating behavior occurred daily. From the 16 residents (labeled as ID), 11 scored 0
on all four behavior measures; three scored three 0’s and one 2 on the four measures; one
scored two 0’s and two 2’s on the four measures; one scored three 0’s and one 3 on the
four measures. Agitation scores are shown in Table 1.
Regarding STM, possible scores are 00-15 (15 indicating the most cognitively
intact). STM was measured four times over the 1-year period. Some residents’ STM
varied slightly and others’ more significantly over the 1-year period. STM scores are
shown in Table 1.
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Table 1
Characteristics of the Study Sample
ID

Time

1
1
1
1
2
2
2
2
3
3
3
3
4
4
4
4
5
5
5
5
6
6
6
6
7
7
7
7
8
8
8
8
9

1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1

Depakote start
date
1/31/13

5/321/15

1/30/16

10/25/14

12/27/15

5/31/15

2/22/14

7/26/13

9/28/13

Agitation

STM score

0
0
0
2
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0

07
02
04
00
08
00
00
00
09
14
14
15
00
00
00
00
14
12
10
10
13
15
14
14
06
07
07
07
00
00
00
00
15
(table continues)
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ID

Time

9
9
9
10
10
10
10
11
11
11
11
12
12
12
12
13
13
13
13
14
14
14
14
15
15
15
15
16
16
16
16

2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4

Depakote Start
Date

5/31/15

1/23/16

7/29/13

10/24/15

10/25/14

6/28/15

7/19/13

Agitation

STM Score

0
0
0
0
0
0
0
0
2
2
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
0
0
0
0

15
15
12
00
00
01
00
00
13
13
15
05
06
12
04
14
14
12
13
15
15
15
15
11
11
06
11
00
00
00
00
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Data Screening
Before data analysis, data were screened to ensure residents met selection criteria.
The consulting pharmacy provided the two NHs with data from the residents who met
study criteria. Study criteria were as follows: residents had to be on Depakote for the 1year period, had to have a diagnosis of dementia, and had to be prescribed Depakote to
treat agitation, Residents on Depakote for other diagnoses were excluded. This allowed
the NHs to provide me with a final deidentified data set that included 16 residents with a
diagnosis of dementia who were receiving Depakote for agitation for the 1-year period
addressed in this study. The MDS was the tool used for assessment measures, and four
quarterly MDSs per resident were provided for repeated-measures ANOVA with withinsubject effects.
Overview of Design and Procedures
Agitation and STM were assessed for each resident through archival data from the
pharmacy consultant and the two NHs. The MDS was the instrument used by the NHs for
initial assessments, and MDS data were provided to me for analysis. The MDS was used
to determine the resident’s agitation and cognitive scores over a 1-year period. The
sections of the MDS that were used to measure the resident’s agitation and cognition
scores were Section C (Cognition) and Section E (Behavior). The agitation scores ranged
from 0 to 3. Out of the 64 repeated measures, there were five scores of 2, one score of 3,
and 58 scores of 0. The STM scores ranged from 00 to 15 and varied from resident to
resident. The mean and SD of agitation were 0.20 and 0.65. The mean and SD for STM
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were 7.5 and 6.10. The mean scores and standard deviations for the dependent variables
are shown in Table 2.
Table 2
Descriptive Statistics for Agitation and STM
Variable

Mean

SD

Agitation

0.20

0.65

STM

7.5

6.10

Data Analysis Results and Major Findings
To test the hypotheses and examine the impact of Depakote on agitation and STM
in NH dementia residents over a 1-year period, I conducted a repeated-measures withinsubjects ANOVA; however; because of possible correlation within the subjects, I
employed boxplots to determine whether the length of time residents were on Depakote
had any significance. Data were analyzed using R Statistical Software Version 3.3.1 for
Windows or Mac. Preliminary tests were done on the data before running the repeatedmeasures ANOVA. Simple plots and boxplots were employed to get an overall view of
the data before proceeding to more complex analyses using repeated-measures ANOVA.
The simple plots in Figure 1 and Figure 2 showed no clear increasing or decreasing
pattern for agitation and STM scores over time.
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Figure 1. Simple plots for agitation scores over a 1-year period.

Figure 2. Simple plots for STM scores over a 1-year period.
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To simplify the data, I used boxplots with differences between time intervals. The
boxplots in Figure 3 and Figure 4 indicated no difference between the scores after another
time interval by having medians close to 0 for all cases.

Figure 3. Boxplots for differences in agitation over each quarter.

Figure 4. Boxplots for differences in STM over each quarter.
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To rule out the effect of varying Depakote start dates; the differences in scores
over time were compared to the number of months from the Depakote start date to the
start of the study. The boxplots in Figure 5 and Figure 6 show there was no clear
correlation between Depakote start dates to the start of the study and agitation and STM
scores.

Figure 5. Boxplots for differences in agitation scores compared to Depakote start date.
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Figure 6. Boxplots for differences in STM scores compared to Depakote start date.

Repeated measures ANOVA was used to test the difference in agitation over the
1-year period of Depakote treatment. A typical rule-of-thumb for ANOVA is to reject the
null when the p-value is below 0.05. Under this cut-off, there was no significant evidence
to reject the null hypothesis H01 for agitation (F-value 0.07, p-value = 0.7988) and STM
scores (F-value 0.0023, p-value = 0.9617).
A further ANOVA test was done to examine if repeated measures ANOVA was
required with this data set. Accounting for the random effects of ID is the main difference
between an ANOVA and a repeated measures ANOVA. In this test, the ANOVA was
used to check if there was a significant difference model with or without the random
effects of ID. There was no significant difference between with and without random
effects models for agitation (df=3, p-value = 0.2266), however, there was a significant
improvement in the model when accounting for the random effects of ID for STM scores
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(df =3, p-value < 0.0001). A repeated measures ANOVA was required for STM scores;
the repeated measures ANOVA still did not show a significant difference in STM scores
over time.
Research Question 1
To what extent does Depakote treatment affect levels of agitation in NH dementia
residents over a 1-year period?
H01: There is not a statistically significant difference in levels of agitation with
Depakote treatment over a 1-year period as evidenced by no change in agitation from
preexisting data in Section E of the MDS.
Ha1: There is a statistically significant difference in levels of agitation with
Depakote treatment over a 1-year period as evidenced by decreased agitation from
preexisting data in Section E of MDS.
The repeated measures ANOVA found no significant difference (F = 4.96, df =
(3), p = 0.2266) between agitation and Depakote treatment over the 1-year period;
therefore, there was no significant evidence to reject the null hypothesis.
Research Question 2
To what extent does Depakote treatment affect STM in NH dementia residents
over a 1-year period?
H02: There is not a statistically significant difference in STM with Depakote
treatment over a 1-year period as evidenced by no change in STM functioning from
preexisting data in Section C of the MDS.
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Ha2: There is a statistically significant difference in STM with Depakote
treatment over a 1-year period as evidenced by decreased STM functioning from
preexisting data in Section C of MDS.
The repeated measures ANOVA found no significant difference (F = 26.95, df =
(3), p = <.0001) between STM and Depakote treatment over the 1-year period; therefore,
there was no significant evidence to reject the null hypothesis.
Exploratory Analysis of Length of Time on Depakote and Agitation and STM
Although the length of time on Depakote was not used in any of the primary
analyses, it is possible that the effects of length of time on Depakote can impact agitation
and STM scores. Specifically, it might be that a resident who has been on Depakote
treatment for a longer period may have lower agitation scores and higher STM scores.
However, boxplots did not show any clear correlation between length of time on
Depakote and agitation scores. Though findings did show significant differences in the
exploratory analysis of STM scores and length of time on Depakote, results were still not
significant over the 1-year study period.
Summary
Based on the findings of these analyses, the null hypothesis could not be rejected
for the two research questions explored, which examined the impact of Depakote on
agitation and STM in NH dementia residents over a 1-year period. Reported findings
showed that Depakote had no effect on agitation scores over the 1-year period.
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Additionally, with random effects, there was still no significant difference in agitation
scores.
Findings did not support the hypotheses that there were significant differences in
STM scores in NH dementia residents on Depakote over a 1-year period. Although
findings did show significant differences in the exploratory analysis of STM and length
of time on Depakote, results were still not significant over the 1-year study period.
Chapter 5 will include a summary of this study and an explanation of why and how the
study was conducted. Conclusions based on the results and impacts of these conclusions
will be presented. Implications of this study will be discussed, along with
recommendations for future research.
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Chapter 5: Discussion, Conclusion, and Recommendations
Study Overview
The purpose of this nonexperimental study was to examine the impact of
Depakote on agitation and STM in NH dementia residents over a 1-year period. Despite
the vast amount of literature on Depakote used for agitation and its effects on cognition,
the existing studies indicated inconsistent results. Results of the current study indicated
no significant impact of Depakote on agitation and STM scores. Although the length of
time on Depakote was not addressed in primary analyses, testing of IDs with and without
random effects for agitation indicated no significant differences. The current study
findings revealed significant improvement in the model when accounting for random
effects of ID for STM scores, but no significant difference in the repeated-measures
ANOVA in STM scores was found over the 1-year period.
The importance of this study was justified by the dearth of empirical data
regarding Depakote’s impact on agitation and STM in NH dementia residents. The use of
Depakote and its impact on NH dementia residents was well documented in the literature.
However, because of the inconsistent findings in the literature on Depakote’s impact on
agitation and STM in NH dementia residents, this study was needed to clarify the impact
and efficacy of a common yet largely unexamined invasive treatment on an underserved,
vulnerable population. This chapter includes the purpose of the study, the research
questions, and an interpretation of the findings in the context of related literature and the
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theoretical framework. I also describe the limitations of the study, recommendations for
further research, and implications for social change.
Interpretation of Findings
The data analysis was conducted to answer two research questions addressing the
extent to which Depakote treatment affected agitation and STM in NH dementia residents
over a 1-year period. Agitation and STM were measured using the MDS assessment
scores. The dataset was obtained from the two participating NHs following the consulting
pharmacies’ dataset of residents who met the study criteria.
The initial data analysis supported the null hypothesis for Research Question 1.
The alternative hypothesis was not accepted because results indicated that Depakote did
not significantly affect agitation scores over the 1-year period. Even when random effects
were accounted for, there was no significant impact.
The second analysis also supported the null hypothesis for Research Question 2.
The alternative hypothesis was not accepted because results indicated that Depakote did
not affect STM scores over the 1-year period. However, when accounting for random
effects, results showed significant improvement in STM scores. Although random effects
analyses showed significant improvement in STM scores, results did not indicate a
significant difference in STM scores over the 1-year period. Therefore, the null
hypothesis was not rejected.
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Literature Review and Research Findings
This study addressed the inconsistencies in previous research findings based on
Moncrieff and Cohen’s (2009) drug-centered theory, which purported that because
psychoactive medications are extrinsic substances altering how the body works, there are
advantages and disadvantages to their use that should be weighed and distinguished from
the effects of general treatment. Depakote is an anticonvulsant medication used to
manage agitation in approximately 80% of NH residents with dementia (Meeks & Jeste,
2008). Medicare reports showed dementia affects approximately 5 to 8 million
Americans, of which more than half have BPSD (Mittal et al., 2011).
There are many different manifestations of dementia, including cognitive decline,
alterations in mood/thought/behavior, and inability to conduct activities of daily living.
As in the Richter et al. (2015) study, Meinhold et al. (2005) described BPSD as
depression, hallucinations, delusions, agitation, aggression, combativeness, disinhibition,
and hyperactivity, and found that pharmacological measures are often used to control
BPSD. Researchers have noted that Depakote may have some advantages when used for
agitation and aggression in dementia residents because of its lower rates of drug
interactions and adverse effects in the dementia population. Meinhold et al. used
pharmacy databases and MDS assessments to obtain data for residents who were
receiving Depakote for behavior problems related to dementia. Similar to the current
study, some exclusions were applied, such as residents who were receiving Depakote for
seizures. Meinhold et al. found the use of Depakote for agitation and aggression in
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dementia residents was effective, safe, and tolerable. This current study confirmed that
Depakote use did not increase agitation scores, suggesting Depakote is effective for
agitation.
Herrman et al. (2007) reached findings along the same lines, reporting Depakote
is ineffective for managing agitation in NH residents with AD and may be poorly
tolerated in this population. Herrman et al. discussed similar previous randomized
controlled trials that also showed no statistically significant benefits of Depakote on
primary outcome measures, though it showed efficacy for some secondary measures. The
major limitations of that study were the small sample size and crossover design, but
despite these limitations, significant worsening of symptoms during Depakote treatment
was found. Similar to the current study, no significant differences were found with
Depakote treatment, though results showed some efficacy for secondary measures, but
not enough to be significant. A difference between Herrman et al.’s (2007) study and the
current study is that Herrman et al. found a significant worsening of symptoms during
Depakote treatment, and the current study did not indicate that. The current study is also
similar to Herrman et al.’s in that the small sample size could have impacted the results.
STM is the system that temporarily stores and manages information that is
necessary to complete complex cognitive tasks (Ai-Guo et al., 2015). Richter et al. (2015)
showed that one of the adverse effects of Depakote treatment is diminished cognitive
function. Results of the current study indicated that, when accounting for random effects
of the ID for STM scores, there was a significant improvement; however, the repeated-
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measures ANOVA did not show a significant difference in STM scores over the 1-year
period.
Dharmarajan and Gunturu (2009) discussed the high rates of AD in NH residents
and the possible causes. Dharmarajan and Gunturu described AD as a common, acquired
disorder that manifests as slow, progressive memory loss with at least one cognitive
dysfunction (aphasia, apraxia, agnosia, or executive dysfunction), resulting in impaired
occupational and social performance. Dharmarajan and Gunturu discussed (a) the use of
psychoactive medications, including Depakote, to manage agitation and difficult
behaviors in NH dementia residents and (b) the impact of the medication on cognitive
function. Similar to the Richter et al. (2015) study, Dharmarajan and Gunturu addressed
adverse effects and cognitive functioning but not specifically on STM. The current study
did not address other adverse effects, only agitation, and STM scores because there was
little previous research on STM and Depakote. The current study did not indicate any
significant effect of Depakote increasing memory loss, but possibly slowing cognitive
decline. This is because there was no significant difference in STM over the 1-year
period, indicating IDs maintained cognitive functioning over the 1-year period.
Ai-Guo et al. (2015) used mice to examine how astrocytes and microglia activated
by amyloid-β (Aβ) contributed to the inflammatory process that develops around brain
injury. Ai-Guo et al. reported that Depakote had been shown to have an antiinflammatory function, and their study addressed the therapeutic effect of Depakote on
the neuropathology and memory deficits in transgenic mice. Ai-Guo et al. reported that
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mice treated with Depakote showed markedly improved memory deficits and decreased
Aβ deposition compared with the non-Depakote treated mice. Similar to these findings,
results from the current study indicated no differences in STM over the 1-year period;
therefore, there is a possibility that Depakote may contribute to the slower cognitive
decline. In contrast, Manckoundia et al. (2008) found different results of Depakote’s
influence on cognitive functioning. The individual in this case study showed a significant
decline in cognitive functioning once she began the Depakote. The Depakote was then
discontinued due to these adverse effects, and she regained her cognitive function.
When reviewing the literature, I observed considerable inconsistencies in study
findings. Some researchers reported that Depakote was effective for agitation, while other
researchers reported that Depakote increased agitation and other BPSD symptoms. Some
researchers reported that Depakote slowed cognitive decline, while other researchers
indicated that Depakote caused a decline in cognitive functioning.
Theoretical Framework and Research Findings
The theoretical framework for this study was Moncrieff and Cohen’s (2009) drugcentered theory, which suggests that because psychoactive medications are extrinsic
substances altering how the body works, advantages and disadvantages of psychoactive
medication use should be weighed and distinguished from the effects of general
treatment. Drug-centered theory can inform perspectives about how psychological
alterations produced by psychoactive medications interact with experiences of distress
and the need to seek psychological help. Many disorders can mimic psychoactive effects,
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such as sedation, cognitive slowing, behaviors, altered sense of perception, sleep, and
psychosis.
Moncrieff and Cohen (2009) theorized that although evidence of the superiority
of psychoactive medications might imply disease-specific effects, superior effects can
also be explained within a drug-centered framework (e.g., the psychomotor and
emotional restriction characteristic of psychoactive medications suppresses psychotic
agitation more effectively than other sedatives). The drug-centered theory provides a
useful lens through which NH resident clinicians or staff members can evaluate and
report the effects of Depakote treatment in NH dementia residents. The drug-centered
framework further prompts members of the psychiatric research community to produce
relevant, unbiased information about the short- and long-term effects that psychoactive
medications exert on cognition, behaviors, and bodily systems.
Limitations of the Study
One of the limitations of this study was that the sample was drawn from only two
NHs in the United States and did not adequately represent all aspects of the NH
population. Residents were obtained for this study through the two local NHs with
preexisting data. Data collection served as a limitation because there were several
selection criteria: needing to be on Depakote for the 1-year period, having a diagnosis of
dementia, and receiving Depakote treatment for agitation/behaviors. Residents who were
taking Depakote for other reasons were excluded.
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Another limitation was that I assumed that the NH MDS coordinators were
answering the MDS questions accurately and completing the resident/staff interviews on
time. If the resident/staff interviews were not completed each quarter, scores could be
inaccurate. The credibility of findings depended on the honesty and diligence of the data
providers.
Implications for Social Change
Implications for social change include assessing the impact and efficacy of a
common yet largely unexamined invasive treatment on an underserved, vulnerable
population. Much of the existing research on Depakote and STM has been solely focused
on the adverse effects of various psychotropic medications and cognitive functioning;
however, this study specifically employed Depakote because it tends to be the most
widely used medication to treat agitation in NH dementia residents (Richter, Mann,
Meyer, Haastert, & Köpke, 2011). Also, this study specifically looked at how Depakote
effected STM in NH dementia residents. There has been noted research on Depakote and
its impact on cognitive functioning; however, research is lacking in STM. Research on
this subject is fairly complex because members of the target population are often unable
to express how they feel. Therefore, cognitive testing is important in this population in
that it allows for the determination of memory loss. The most common form of memory
loss in dementia residents starts with STM, and this does not seem to be a focus of much
of the existing literature. Therefore, this study focused on how Depakote impacts STM in
NH dementia residents.

82
This research adds to the literature of research conducted solely on the impact of
Depakote on agitation and STM in NH dementia residents. This research can provide
avenues for social change by providing new information to appropriate professionals, on
the most common treatment (i.e., Depakote) for a prevalent and exigent societal problem
(i.e., BPSD).
Recommendations for Future Research
The current study has increased understanding of the impact of Depakote on
agitation and STM in NH dementia residents over a 1-year period. It is recommended that
additional research is done on this topic. The current study used quantitative measures;
however, conducting this study using qualitative measures would possibly produce more
comprehensive analysis and statistical significance as it would gather specific themes that
could be explored to address the impact of Depakote on agitation and STM. Results
indicated there was no significant difference in agitation and STM scores among the 16
residents in this study. Future research should also include residents chosen with specific
demographics and characteristics to broaden the sample criteria.
As research has previously noted, the impact or benefits of psychoactive
medications are not exclusive to one specific medication; thus, the anticonvulsant agent
Depakote may have some advantages when used for agitation and aggression in dementia
residents due to its lower rates of drug interactions and adverse effects in the dementia
population (Meinhold et al., 2005). Previous research has found the use of Depakote for
agitation and aggression in dementia residents was effective, safe, and tolerable. Also, it
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has been found that Depakote may have multiple beneficial effects in NH dementia
residents with a history of dementia with behavioral problems. Additional research is
needed in the areas of (a) using Depakote treatment as a secondary agent and (b) starting
the treatment earlier in the dementia process to explore if it may have more beneficial
effects.
Recommendations for Action
This study provides an understanding of the impact of Depakote on agitation and
STM in NH dementia residents over a 1-year period. There were no significant
relationships or differences between Depakote and agitation scores. A total of 16
residents scores were measured and compared to the other with random effects over a 1year period. Agitation scores varied but were close enough that statistical analysis
showed no significance. With this information, avenues for additional exploration on
Depakote and agitation in NH dementia residents can be explored by utilizing a larger
sample and additional demographics to highlight the effects of Depakote in a larger
population with demographics for a substance to the research.
Although this study did not indicate any statistical significance among Depakote
and STM scores, there is now research on STM and how it is impacted by Depakote
treatment. Research has now highlighted that STM scores improved from Depakote start
date, though not significantly during a 1-year period. This information can potentially
help professionals when completing cognitive testing in NH dementia residents on
Depakote treatment. Notably, this research may provide some awareness into the fact that
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Depakote treatment can play a role in STM; however, appropriate measures must be
taken to maintain confidentiality and safety among members of this vulnerable
population.
Conclusion
This current study focused on a sample of 16 NH residents with a diagnosis of
dementia receiving Depakote treatment for agitation. The research was designed to utilize
preexisting data from the consulting pharmacy and two local NHs. The results of the
repeated measures ANOVA with within-subjects did not reveal a significant relationship
between Depakote and levels of agitation or STM. Results of repeated measures ANOVA
with within subjects and random effects did not reveal a significant relationship between
Depakote and agitation scores but revealed an improvement in STM scores. Although
this study revealed an improvement in STM scores, it did not reveal any significant
difference in STM scores over the 1-year study period. Adding a confounding variable,
length of time on Depakote did not show any significance in agitation or STM scores.
The findings from this study suggest that there may be other factors moderating agitation
and STM scores, and further exploration is warranted on the impact of Depakote on
agitation and STM in NH dementia residents over a 1-year period.
Results from this study also suggest that there is much more to be explored among
the NH dementia population. Because dementia residents are unable to provide
information themselves, the researcher must rely on the NH staff for information. It is
important for future research to be sure that the information received from preexisting
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data is accurate and honest. Without accuracy, results can be affected. Results of this
study also reveal that the sample may be too small and that a larger sample would provide
more substance to the research.
Understanding of these results may lead to earlier administration of Depakote to
NH dementia residents. This research can provide insight to mental health professionals,
medical staff, NH staff, and psychologists regarding the treatment needs of NH dementia
residents experiencing BPSD. I hope that these findings will bring much-needed
awareness to this underserved population so that appropriate care and treatment are
enforced, policies for treatment interventions developed and implemented, education
made available, and future research made a priority. Research can give a voice to this
important and growing population.
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